The Weekly Litigation News Digest is now live. Subscribe now

IP Verse

Vifor Fresenius Medical Care Renal Pharma Ltd. v. Gland Pharma Limited - 1:25-cv-01382

Vifor Fresenius Medical Care Renal Pharma Ltd. v. Gland Pharma Limited (Case No. 1:25-cv-01382), filed on Nov 13, 2025 in the District Court, D. Delaware involving patent infringement. This case involves patent infringement claims between the parties. Explore details about the litigants, key filings, and major docket updates.

Case Details

Case Number
1:25-cv-01382
Filing Date
Nov 13, 2025
Cause of Action
Patent Infringement
Status
OPEN
Court
District Court, D. Delaware
Nature of Suit
Patent - Abbreviated New Drug Application(ANDA)

Parties Involved

The following parties are involved in this case, with their respective legal representatives for the case.

NameRepresented By
Somerset Therapeutics, LLC -
Odin Pharmaceuticals LLC -
Qilu Pharmaceutical (Hainan) Co., Ltd. -
Gland Pharma Limited -
Vifor (International), Inc. -

Patents Involved

This case involves 12 patents, each of which is central to the dispute. These patents may be subject to claims of infringement, challenges to their validity, or other issues concerning their scope and enforcement.

Application NumberPatent Number
-US8217007B2
-US8486894B2
-US9334305B2
-US10793596B2
-US10017536B2
-US9359399B2
-US10138270B2
-US7727963B2
-US8236766B2
-US8536131B2
-US7402564B2
-US7713937B2

Docket Entries

The Docket Entries section provides a chronological list of all significant filings and court actions in this case.

DateDocket EntryType

Set alerts for critical docket entry

Nov 13, 2025Disclosure Statement pursuant to Rule 7.1: Other Affiliates Vifor Pharma Participations, AG, Fresenius Medical Care AG, CSL Behring AG, CSL Behring Holdings Limited, CSL Behring (Holdings) Pty Ltd., CSL Limited, for Vifor Fresenius Medical Care Renal Pharma Ltd.; Corporate Parent Vifor Pharma Participations, AG and Other Affiliates CSL Behring AG, CSL Behring Holdings Limited, CSL Behring (Holdings) Pty Ltd., CSL Limited for Vifor (International), Inc., filed by Vifor (International), Inc., Vifor Fresenius Medical Care Renal Pharma Ltd.. (slk) (Entered: 11/14/2025)PACER Document
Nov 13, 2025Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) U.S. 7,402,564; U.S. 7,713,937; U.S. 7,727,963; U.S. 8,217,007; U.S. 8,236,766; U.S. 8,486,894; U.S. 8,536,131; U.S. 9,334,305; U.S. 9,359,399; U.S. 10,017,536; U.S. 10,138,270; U.S. 10,793,596. (slk) (Entered: 11/14/2025)PACER Document
Nov 13, 2025Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: Gland Pharma Limiteds Paragraph IV Notice: October 6, 2025, Somerset Therapeutics, LLC and Odin Pharmaceuticals, LLCs Paragraph IV Notice: October 1, 2025 & Qilu Pharma, Inc. and Qilu Pharmaceutical (Hainan) Co., Ltd.s Paragraph IV Notice: October 1, 2025. Date of Expiration of Patent: U.S. Patent No. 7,402,564: November 12, 2027, to be extended to November 12, 2032, U.S. Patent Nos. 7,713,937, 7,727,963, 8,217,007, 8,236,766,8,486,894, 8,536,131, 9,334,305,9,359,399, 10,017,536, 10,138,270, 10,793,596: November 12, 2027.Thirty Month Stay Deadline: 2/23/2029. (slk) (Entered: 11/14/2025)PACER Document
Nov 13, 2025Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (slk) (Entered: 11/14/2025)PACER Document
Nov 13, 2025COMPLAINT for Patent Infringement against Gland Pharma Limited, Odin Pharmaceuticals LLC, Qilu Pharma, Inc., Qilu Pharmaceutical (Hainan) Co., Ltd., Somerset Therapeutics, LLC (Filing fee $ 405, receipt number ADEDC-4837040) - filed by Vifor Fresenius Medical Care Renal Pharma Ltd., Vifor (International), Inc. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Civil Cover Sheet)(slk) (Entered: 11/14/2025)PACER Document
Nov 14, 2025No Summons Issued. (slk)PACER Document